Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences (Nasdaq: RNA) announced multiple presentations at the 2025 MDA Clinical & Scientific Conference in Dallas, Texas from March 16-19, 2025. The highlight includes presentation of topline data for del-zota from the Phase 1/2 EXPLORE44 trial, showing statistically significant increases in exon skipping and dystrophin levels in DMD44 patients.
Key events include:
- An oral presentation by Dr. Aravindhan Veerapandiyan on March 19
- Two poster presentations on del-zota results and the HARBOR™ trial design
- An industry forum breakfast on March 17 titled 'Advancing RNA Therapeutics' featuring expert panel discussion
- An investor and analyst webcast on March 17 to discuss EXPLORE44 trial data
The company will make presentations and posters available on their website following the conference.
Avidity Biosciences (Nasdaq: RNA) ha annunciato numerose presentazioni alla 2025 MDA Clinical & Scientific Conference che si terrà a Dallas, Texas, dal 16 al 19 marzo 2025. Il punto culminante include la presentazione dei dati preliminari per del-zota dal trial di Fase 1/2 EXPLORE44, che mostrano aumenti statisticamente significativi nell'eson skipping e nei livelli di distrofina nei pazienti DMD44.
Gli eventi principali includono:
- Una presentazione orale del Dr. Aravindhan Veerapandiyan il 19 marzo
- Due presentazioni poster sui risultati di del-zota e sul design del trial HARBOR™
- Una colazione di forum industriale il 17 marzo intitolata 'Avanzare nelle Terapie RNA' con una discussione di esperti
- Un webcast per investitori e analisti il 17 marzo per discutere i dati del trial EXPLORE44
La società renderà disponibili presentazioni e poster sul proprio sito web dopo la conferenza.
Avidity Biosciences (Nasdaq: RNA) anunció múltiples presentaciones en la 2025 MDA Clinical & Scientific Conference en Dallas, Texas, del 16 al 19 de marzo de 2025. El punto culminante incluye la presentación de datos preliminares para del-zota del ensayo de Fase 1/2 EXPLORE44, que muestra aumentos estadísticamente significativos en el skipping de exones y los niveles de distrofina en pacientes DMD44.
Los eventos clave incluyen:
- Una presentación oral del Dr. Aravindhan Veerapandiyan el 19 de marzo
- Dos presentaciones en cartel sobre los resultados de del-zota y el diseño del ensayo HARBOR™
- Un desayuno de foro industrial el 17 de marzo titulado 'Avanzando en Terapias de RNA' con una discusión de expertos
- Un webcast para inversores y analistas el 17 de marzo para discutir los datos del ensayo EXPLORE44
La empresa hará disponibles presentaciones y carteles en su sitio web después de la conferencia.
Avidity Biosciences (Nasdaq: RNA)는 2025년 3월 16일부터 19일까지 텍사스주 달라스에서 열리는 2025 MDA Clinical & Scientific Conference에서 여러 발표를 할 것이라고 발표했습니다. 주요 내용은 DMD44 환자에서 엑손 스키핑 및 디스트로핀 수치의 통계적으로 유의미한 증가를 보여주는 EXPLORE44 1/2상 시험의 del-zota에 대한 주요 데이터 발표입니다.
주요 이벤트는 다음과 같습니다:
- 3월 19일 아라빈단 비라판디안 박사의 구두 발표
- del-zota 결과 및 HARBOR™ 시험 설계에 대한 두 개의 포스터 발표
- 3월 17일 'RNA 치료의 발전'이라는 제목의 산업 포럼 아침식사, 전문가 패널 토론 포함
- 3월 17일 EXPLORE44 시험 데이터를 논의하기 위한 투자자 및 분석가 웹캐스트
회사는 회의 후 자사 웹사이트에 발표 자료 및 포스터를 제공할 것입니다.
Avidity Biosciences (Nasdaq: RNA) a annoncé plusieurs présentations lors de la 2025 MDA Clinical & Scientific Conference qui se tiendra à Dallas, Texas, du 16 au 19 mars 2025. Le point fort inclut la présentation des données préliminaires pour del-zota de l'essai de Phase 1/2 EXPLORE44, montrant des augmentations statistiquement significatives du skipping d'exons et des niveaux de dystrophine chez les patients DMD44.
Les événements clés incluent:
- Une présentation orale du Dr. Aravindhan Veerapandiyan le 19 mars
- Deux présentations par affiche sur les résultats de del-zota et le design de l'essai HARBOR™
- Un petit-déjeuner forum industriel le 17 mars intitulé 'Avancer dans les Thérapeutiques à base d'ARN' avec une discussion d'experts
- Un webcast pour investisseurs et analystes le 17 mars pour discuter des données de l'essai EXPLORE44
L'entreprise mettra à disposition des présentations et des affiches sur son site web après la conférence.
Avidity Biosciences (Nasdaq: RNA) gab bekannt, dass sie mehrere Präsentationen auf der 2025 MDA Clinical & Scientific Conference in Dallas, Texas, vom 16. bis 19. März 2025 halten werden. Der Höhepunkt ist die Präsentation der vorläufigen Daten für del-zota aus der Phase 1/2 EXPLORE44-Studie, die statistisch signifikante Erhöhungen im Exon-Skipping und den Dystrophin-Spiegeln bei DMD44-Patienten zeigt.
Wichtige Veranstaltungen sind:
- Eine mündliche Präsentation von Dr. Aravindhan Veerapandiyan am 19. März
- Zwei Posterpräsentationen zu den Ergebnissen von del-zota und dem HARBOR™ Studien-Design
- Ein Branchenforum-Frühstück am 17. März mit dem Titel 'Fortschritt der RNA-Therapeutika', das eine Expertenpanel-Diskussion umfasst
- Ein Webcast für Investoren und Analysten am 17. März zur Diskussion der EXPLORE44 Studiendaten
Das Unternehmen wird Präsentationen und Poster nach der Konferenz auf seiner Website zur Verfügung stellen.
- None.
- None.
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of
Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET
Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. CT/8:00 a.m. ET
2025 MDA Clinical & Scientific Conference Oral & Poster Presentations
March 19, 2025: 9:00 a.m. – 9:15 a.m. CT
- Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation)
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of
Arkansas for Medical Sciences and Arkansas Children's Hospital, and EXPLORE44® trial investigator, will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44).
March 16-18, 2025: 6:00 p.m. – 8:00 p.m. CT
- Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (poster presentation)
- Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1: HARBOR™ trial design (poster presentation)
The presentation and posters will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com following the conference.
Avidity Sponsored Industry Forum Breakfast Event During MDA Conference
On March 17, 2025, 7:00 a.m. CT, Mike Flanagan, PhD, Chief Scientific Officer at Avidity, will host an industry forum breakfast titled "Advancing RNA Therapeutics: Exploring Antibody Oligonucleotide Conjugates (AOCs) for Rare Neuromuscular Diseases." Dr. Flanagan will be joined by guest speaker, Nicholas E. Johnson, MD, MSCI, FAAN, Vice Chair for Research, Department of Neurology,
Avidity Investor and Analyst Webcast
Avidity management will be joined by Kevin Flanigan, MD, Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children's Hospital, and Professor of Pediatrics and Neurology at the
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical--scientific-conference-302400330.html
SOURCE Avidity Biosciences, Inc.
FAQ
What are the key findings of Avidity Biosciences' del-zota drug in the EXPLORE44 trial?
When will Avidity Biosciences (RNA) present the EXPLORE44 trial results?
What events is Avidity Biosciences (RNA) hosting during the 2025 MDA Conference?
What is the focus of Avidity Biosciences' (RNA) presentations at the 2025 MDA Conference?
